Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02103920
Other study ID # MC01/06/11
Secondary ID
Status Recruiting
Phase N/A
First received April 2, 2012
Last updated April 1, 2014
Start date May 2011

Study information

Verified date April 2014
Source National University Hospital, Singapore
Contact Ross Soo, MBBS
Phone +65 6779 5555
Email Ross_Soo@nuhs.edu.sg
Is FDA regulated No
Health authority Singapore: Domain Specific Review Boards
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the expression of molecules involved in the glycine/serine pathway using immunohistochemistry in solid tumors. Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained. Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort. To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong). Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma. One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. Patient Identifiers will not be collected. Societal benefit in terms of knowledge gained to improve understanding of cancer. No direct risk to subjects as this is a retrospective study of archived pathological tumour samples.


Recruitment information / eligibility

Status Recruiting
Enrollment 1400
Est. completion date
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Patients with solid tumor cancer

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
Singapore Nationa University Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change the expression of molecules of putative relevance to the glycine/serine pathway Archived paraffin-embedded pathological specimens from the Department of Pathology, NUH will be obtained. Tissue microarray (TMA) is a high-throughput method of analysing large numbers of formalin-fixed, paraffin-embedded tumor at a minimal cost and effort. To analyse the expression of molecules of putative relevance to the glycine/serine pathway, (such as PSPH, PSAT1, SHMT1, and GLDC), TMA technology will be utilised as previously reported (Kristiansen, Zhang, Soong). Tissue arrays will be constructed from solid tumors including cancers of the colon/ rectum, lung, breast, cervix, ovary, endometrium, fallopian tube, prostate, kidney, testis, stomach, liver, brain and lymphoma. One hundred cases of each tumor type (subject to availability) will be stained using immunohistochemistry. 5 years No
See also
  Status Clinical Trial Phase
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Completed NCT00046111 - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors Phase 1
Completed NCT00119171 - Ispinesib In Combination With Capecitabine In Patients With Solid Tumors Phase 1
Recruiting NCT04354064 - Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Completed NCT00169520 - SB-715992 In Combination With Docetaxel In Patients With Solid Tumors Phase 1
Completed NCT00085878 - Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors Phase 1
Completed NCT00136513 - SB-743921 In Patients With Solid Tumors Phase 1
Completed NCT00085904 - Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas Phase 1
Completed NCT06042400 - Trial of Written Exposure for Metastatic Cancer Patients (EASE) N/A